Home » Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag

Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag

by Ghassan

by Khushi Mandowara

(MAINNEWS) – Moderna Inc (MRNA.O) said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc’s (MRK.N) drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.

Shares of Moderna rise 2.5% to $164 after the market.

The breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer’s recurrence or death by 44% compared with Keytruda alone.

The FDA’s breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.

Join our U.S Main News community and be the first to hear the news!

The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023.

Leave a Comment

U.S MainNews Logo
U.S Main News will keep you informed on the latest and most significant local and international events, including sports news and entertainment stories, providing readers with up-to-date coverage and breaking news.


Get your daily dose of news and events here!

Latest News

© Copyright 2022, All Rights Reserved | U.S. Main News